The Health Care Select Sector SPDR® Fund ETF (NYSEARCA:XLV), which tracks the health care sector, and holds a weightage of 12 ...

A journey through the FDA’s newly released complete response letters gave glimpses into the journeys to market for Eli ...

Amarna Therapeutics and NorthX Biologics finalized an agreement to advance Nimvec AM510 gene therapy toward clinical trials for Type 1 Diabetes. Now in its fourth year, the MM+M Media Summit brings ...

A twice-yearly injection could help Australia eliminate HIV, but experts are sounding the alarm over its prohibitive cost.

Trump administration funding cuts and dismantling of USAID force a shift from HIV elimination back to treatment.

This was the stock's second consecutive day of gains.

We came across a bullish thesis on Gilead Sciences, Inc. on Dividend Talks’s Substack. In this article, we will summarize the ...

The Minister’s address was particularly notable for the announcement of a planned rollout of lenacapavir, a biannual ...

Gilead has partnered with Global Fund to supply lenacapavir for the prevention of HIV as pre-exposure prophylaxis (PrEP).

Arcus Biosciences' cancer drug candidate, quemliclustat, earns FDA orphan drug status, ensuring incentives and exclusivity.

Woven Health Collective announced Wednesday that it has acquired Boundless Life Sciences Group. The 2025 MM+M Agency 100 honoree bought the 2024 MM+M Agency 100 honoree in a bid to build out its ...

Pomerantz LLP is investigating claims on behalf of investors of Gilead Sciences, Inc. (“Gilead” or the “Company”) (NASDAQ: GILD). Such investors are ...